http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 30 Sep 2026 11:57:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Celularity+Highlights+Anticipated+Quarter+One+2027+Opening+of+Fontaine+Vitale+as+Strategic+Partner/27127405.html <p>FLORHAM PARK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today highlighted continued progress at Fontaine Vitale, a regenerative medicine and wellness center being developed in the Sanur Special Economic Zone (“Sanur SEZ”) in Bali, Indonesia, in anticipation of its grand opening in the first quarter of 2027.</p> <p>Developed by Genting Berhad and its Indonesian partners with strategic collaboration and input from Celularity, Fontaine Vitale is designed to serve local and international patients seeking advanced wellness, aesthetics, longevity and http://www.streetinsider.com/Press+Releases/Celularity+Highlights+Anticipated+Quarter+One+2027+Opening+of+Fontaine+Vitale+as+Strategic+Partner/27127405.html Wed, 30 Sep 2026 11:57:00 -0400 CELU CELUW http://www.streetinsider.com/Globe+Newswire/Celularity+Highlights+Anticipated+Quarter+One+2027+Opening+of+Fontaine+Vitale+as+Strategic+Partner/27127405.html <p>FLORHAM PARK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today highlighted continued progress at Fontaine Vitale, a regenerative medicine and wellness center being developed in the Sanur Special Economic Zone (“Sanur SEZ”) in Bali, Indonesia, in anticipation of its grand opening in the first quarter of 2027.</p> <p>Developed by Genting Berhad and its Indonesian partners with strategic collaboration and input from Celularity, Fontaine Vitale is designed to serve local and international patients seeking advanced wellness, aesthetics, longevity and http://www.streetinsider.com/Globe+Newswire/Celularity+Highlights+Anticipated+Quarter+One+2027+Opening+of+Fontaine+Vitale+as+Strategic+Partner/27127405.html Wed, 30 Sep 2026 11:57:00 -0400 CELU CELUW http://www.streetinsider.com/Press+Releases/Celularity+Highlights+Anticipated+Quarter+One+2027+Opening+of+Fontaine+Vitale+as+Strategic+Partner/27127405.html <p>FLORHAM PARK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today highlighted continued progress at Fontaine Vitale, a regenerative medicine and wellness center being developed in the Sanur Special Economic Zone (“Sanur SEZ”) in Bali, Indonesia, in anticipation of its grand opening in the first quarter of 2027.</p> <p>Developed by Genting Berhad and its Indonesian partners with strategic collaboration and input from Celularity, Fontaine Vitale is designed to serve local and international patients seeking advanced wellness, aesthetics, longevity and http://www.streetinsider.com/Press+Releases/Celularity+Highlights+Anticipated+Quarter+One+2027+Opening+of+Fontaine+Vitale+as+Strategic+Partner/27127405.html Wed, 30 Sep 2026 11:57:00 -0400 CELU CELUW http://www.streetinsider.com/Globe+Newswire/Celularity+Highlights+Anticipated+Quarter+One+2027+Opening+of+Fontaine+Vitale+as+Strategic+Partner/27127405.html <p>FLORHAM PARK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today highlighted continued progress at Fontaine Vitale, a regenerative medicine and wellness center being developed in the Sanur Special Economic Zone (“Sanur SEZ”) in Bali, Indonesia, in anticipation of its grand opening in the first quarter of 2027.</p> <p>Developed by Genting Berhad and its Indonesian partners with strategic collaboration and input from Celularity, Fontaine Vitale is designed to serve local and international patients seeking advanced wellness, aesthetics, longevity and http://www.streetinsider.com/Globe+Newswire/Celularity+Highlights+Anticipated+Quarter+One+2027+Opening+of+Fontaine+Vitale+as+Strategic+Partner/27127405.html Wed, 30 Sep 2026 11:57:00 -0400 CELU CELUW http://www.streetinsider.com/Corporate+News/Celularity+CEO+comments+on+Medicare+skin+substitute+rule+withdrawal/25779869.html <p>Celularity Inc. (NASDAQ: CELU) released comments from CEO Robert J. Hariri regarding the Centers for Medicare & Medicaid Services' withdrawal of skin substitute Local Coverage Determinations that were scheduled to take effect January 1, 2026.</p><p>CMS announced December 24 that Medicare Administrative Contractors were immediately withdrawing the LCDs for skin substitute grafts and cellular products used to treat diabetic foot ulcers and venous leg ulcers. The withdrawn rules would have eliminated Medicare coverage for 158 skin substitute products from other companies while maintaining coverage for Celularity's Biovance and Biovance 3L products.</p><p>The withdrawal does not affect CMS's new payment policy setting skin http://www.streetinsider.com/Corporate+News/Celularity+CEO+comments+on+Medicare+skin+substitute+rule+withdrawal/25779869.html Fri, 26 Dec 2025 08:31:25 -0400 CELU CELUW http://www.streetinsider.com/Corporate+News/Celularity+CEO+comments+on+Medicare+skin+substitute+rule+withdrawal/25779869.html <p>Celularity Inc. (NASDAQ: CELU) released comments from CEO Robert J. Hariri regarding the Centers for Medicare & Medicaid Services' withdrawal of skin substitute Local Coverage Determinations that were scheduled to take effect January 1, 2026.</p><p>CMS announced December 24 that Medicare Administrative Contractors were immediately withdrawing the LCDs for skin substitute grafts and cellular products used to treat diabetic foot ulcers and venous leg ulcers. The withdrawn rules would have eliminated Medicare coverage for 158 skin substitute products from other companies while maintaining coverage for Celularity's Biovance and Biovance 3L products.</p><p>The withdrawal does not affect CMS's new payment policy setting skin http://www.streetinsider.com/Corporate+News/Celularity+CEO+comments+on+Medicare+skin+substitute+rule+withdrawal/25779869.html Fri, 26 Dec 2025 08:31:25 -0400 CELU CELUW http://www.streetinsider.com/Press+Releases/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html <p align="justify">FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Centers for Medicare &amp; Medicaid Services’ (CMS) recent withdrawal of skin substitute Local Coverage Determinations (LCDs) that were set to go into effect on January 1, 2026.</p> <p align="justify">On December 24, 2025, CMS announced that effective immediately, A/B Medicare Administrative Contractors (MACs) were withdrawing the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of http://www.streetinsider.com/Press+Releases/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html Fri, 26 Dec 2025 08:30:00 -0400 A.50201632 CELU CELUW O.13850319 O.37572456 http://www.streetinsider.com/Globe+Newswire/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html <p align="justify">FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Centers for Medicare &amp; Medicaid Services’ (CMS) recent withdrawal of skin substitute Local Coverage Determinations (LCDs) that were set to go into effect on January 1, 2026.</p> <p align="justify">On December 24, 2025, CMS announced that effective immediately, A/B Medicare Administrative Contractors (MACs) were withdrawing the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of http://www.streetinsider.com/Globe+Newswire/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html Fri, 26 Dec 2025 08:30:00 -0400 A.50201632 CELU CELUW O.13850319 O.37572456 http://www.streetinsider.com/Press+Releases/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html <p align="justify">FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Centers for Medicare &amp; Medicaid Services’ (CMS) recent withdrawal of skin substitute Local Coverage Determinations (LCDs) that were set to go into effect on January 1, 2026.</p> <p align="justify">On December 24, 2025, CMS announced that effective immediately, A/B Medicare Administrative Contractors (MACs) were withdrawing the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of http://www.streetinsider.com/Press+Releases/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html Fri, 26 Dec 2025 08:30:00 -0400 A.50201632 CELU CELUW O.13850319 O.37572456 http://www.streetinsider.com/Globe+Newswire/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html <p align="justify">FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Centers for Medicare &amp; Medicaid Services’ (CMS) recent withdrawal of skin substitute Local Coverage Determinations (LCDs) that were set to go into effect on January 1, 2026.</p> <p align="justify">On December 24, 2025, CMS announced that effective immediately, A/B Medicare Administrative Contractors (MACs) were withdrawing the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of http://www.streetinsider.com/Globe+Newswire/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html Fri, 26 Dec 2025 08:30:00 -0400 A.50201632 CELU CELUW O.13850319 O.37572456 http://www.streetinsider.com/Press+Releases/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html <p align="justify">FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Centers for Medicare &amp; Medicaid Services’ (CMS) recent withdrawal of skin substitute Local Coverage Determinations (LCDs) that were set to go into effect on January 1, 2026.</p> <p align="justify">On December 24, 2025, CMS announced that effective immediately, A/B Medicare Administrative Contractors (MACs) were withdrawing the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of http://www.streetinsider.com/Press+Releases/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html Fri, 26 Dec 2025 08:30:00 -0400 A.50201632 CELU CELUW O.13850319 O.37572456 http://www.streetinsider.com/Globe+Newswire/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html <p align="justify">FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Centers for Medicare &amp; Medicaid Services’ (CMS) recent withdrawal of skin substitute Local Coverage Determinations (LCDs) that were set to go into effect on January 1, 2026.</p> <p align="justify">On December 24, 2025, CMS announced that effective immediately, A/B Medicare Administrative Contractors (MACs) were withdrawing the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of http://www.streetinsider.com/Globe+Newswire/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html Fri, 26 Dec 2025 08:30:00 -0400 A.50201632 CELU CELUW O.13850319 O.37572456 http://www.streetinsider.com/Press+Releases/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html <p align="justify">FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Centers for Medicare &amp; Medicaid Services’ (CMS) recent withdrawal of skin substitute Local Coverage Determinations (LCDs) that were set to go into effect on January 1, 2026.</p> <p align="justify">On December 24, 2025, CMS announced that effective immediately, A/B Medicare Administrative Contractors (MACs) were withdrawing the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of http://www.streetinsider.com/Press+Releases/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html Fri, 26 Dec 2025 08:30:00 -0400 A.50201632 CELU CELUW O.13850319 O.37572456 http://www.streetinsider.com/Globe+Newswire/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html <p align="justify">FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Centers for Medicare &amp; Medicaid Services’ (CMS) recent withdrawal of skin substitute Local Coverage Determinations (LCDs) that were set to go into effect on January 1, 2026.</p> <p align="justify">On December 24, 2025, CMS announced that effective immediately, A/B Medicare Administrative Contractors (MACs) were withdrawing the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of http://www.streetinsider.com/Globe+Newswire/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html Fri, 26 Dec 2025 08:30:00 -0400 A.50201632 CELU CELUW O.13850319 O.37572456 http://www.streetinsider.com/Press+Releases/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html <p align="justify">FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Centers for Medicare &amp; Medicaid Services’ (CMS) recent withdrawal of skin substitute Local Coverage Determinations (LCDs) that were set to go into effect on January 1, 2026.</p> <p align="justify">On December 24, 2025, CMS announced that effective immediately, A/B Medicare Administrative Contractors (MACs) were withdrawing the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of http://www.streetinsider.com/Press+Releases/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html Fri, 26 Dec 2025 08:30:00 -0400 A.50201632 CELU CELUW O.13850319 O.37572456 http://www.streetinsider.com/Globe+Newswire/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html <p align="justify">FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Centers for Medicare &amp; Medicaid Services’ (CMS) recent withdrawal of skin substitute Local Coverage Determinations (LCDs) that were set to go into effect on January 1, 2026.</p> <p align="justify">On December 24, 2025, CMS announced that effective immediately, A/B Medicare Administrative Contractors (MACs) were withdrawing the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of http://www.streetinsider.com/Globe+Newswire/Celularity+CEO+Comments+on+Centers+for+Medicare+%26amp%3B+Medicaid+Services%E2%80%99+Withdrawal+of+Skin+Substitute+Local+Coverage+Determinations/25779861.html Fri, 26 Dec 2025 08:30:00 -0400 A.50201632 CELU CELUW O.13850319 O.37572456 http://www.streetinsider.com/Press+Releases/Celularity+Announces+Filing+of+Form+10-Q+Quarterly+Reports+for+the+First+Quarter+and+the+Second+Quarter+2025%2C+Confirmation+of+Nasdaq+Listing+Rule+5250%28c%29%281%29+Compliance/25288702.html <ul><li style="text-align:left;">Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan.</li><li style="margin-bottom:8pt; text-align:left;">Company also announces notification by Nasdaq dated September 2, 2025, that it now complies with Nasdaq Listing Rule 5250(c)(1).</li></ul> <p>FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced the filing of its Quarterly Report on Form 10-Q for the quarter http://www.streetinsider.com/Press+Releases/Celularity+Announces+Filing+of+Form+10-Q+Quarterly+Reports+for+the+First+Quarter+and+the+Second+Quarter+2025%2C+Confirmation+of+Nasdaq+Listing+Rule+5250%28c%29%281%29+Compliance/25288702.html Wed, 03 Sep 2025 08:00:00 -0400 CELU CELUW O.37572456 http://www.streetinsider.com/Globe+Newswire/Celularity+Announces+Filing+of+Form+10-Q+Quarterly+Reports+for+the+First+Quarter+and+the+Second+Quarter+2025%2C+Confirmation+of+Nasdaq+Listing+Rule+5250%28c%29%281%29+Compliance/25288702.html <ul><li style="text-align:left;">Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan.</li><li style="margin-bottom:8pt; text-align:left;">Company also announces notification by Nasdaq dated September 2, 2025, that it now complies with Nasdaq Listing Rule 5250(c)(1).</li></ul> <p>FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced the filing of its Quarterly Report on Form 10-Q for the quarter http://www.streetinsider.com/Globe+Newswire/Celularity+Announces+Filing+of+Form+10-Q+Quarterly+Reports+for+the+First+Quarter+and+the+Second+Quarter+2025%2C+Confirmation+of+Nasdaq+Listing+Rule+5250%28c%29%281%29+Compliance/25288702.html Wed, 03 Sep 2025 08:00:00 -0400 CELU CELUW O.37572456 http://www.streetinsider.com/Press+Releases/Celularity+Announces+Filing+of+Form+10-Q+Quarterly+Reports+for+the+First+Quarter+and+the+Second+Quarter+2025%2C+Confirmation+of+Nasdaq+Listing+Rule+5250%28c%29%281%29+Compliance/25288702.html <ul><li style="text-align:left;">Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan.</li><li style="margin-bottom:8pt; text-align:left;">Company also announces notification by Nasdaq dated September 2, 2025, that it now complies with Nasdaq Listing Rule 5250(c)(1).</li></ul> <p>FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced the filing of its Quarterly Report on Form 10-Q for the quarter http://www.streetinsider.com/Press+Releases/Celularity+Announces+Filing+of+Form+10-Q+Quarterly+Reports+for+the+First+Quarter+and+the+Second+Quarter+2025%2C+Confirmation+of+Nasdaq+Listing+Rule+5250%28c%29%281%29+Compliance/25288702.html Wed, 03 Sep 2025 08:00:00 -0400 CELU CELUW O.37572456 http://www.streetinsider.com/Globe+Newswire/Celularity+Announces+Filing+of+Form+10-Q+Quarterly+Reports+for+the+First+Quarter+and+the+Second+Quarter+2025%2C+Confirmation+of+Nasdaq+Listing+Rule+5250%28c%29%281%29+Compliance/25288702.html <ul><li style="text-align:left;">Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan.</li><li style="margin-bottom:8pt; text-align:left;">Company also announces notification by Nasdaq dated September 2, 2025, that it now complies with Nasdaq Listing Rule 5250(c)(1).</li></ul> <p>FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced the filing of its Quarterly Report on Form 10-Q for the quarter http://www.streetinsider.com/Globe+Newswire/Celularity+Announces+Filing+of+Form+10-Q+Quarterly+Reports+for+the+First+Quarter+and+the+Second+Quarter+2025%2C+Confirmation+of+Nasdaq+Listing+Rule+5250%28c%29%281%29+Compliance/25288702.html Wed, 03 Sep 2025 08:00:00 -0400 CELU CELUW O.37572456 http://www.streetinsider.com/Press+Releases/Celularity+Announces+Filing+of+Form+10-Q+Quarterly+Reports+for+the+First+Quarter+and+the+Second+Quarter+2025%2C+Confirmation+of+Nasdaq+Listing+Rule+5250%28c%29%281%29+Compliance/25288702.html <ul><li style="text-align:left;">Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan.</li><li style="margin-bottom:8pt; text-align:left;">Company also announces notification by Nasdaq dated September 2, 2025, that it now complies with Nasdaq Listing Rule 5250(c)(1).</li></ul> <p>FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced the filing of its Quarterly Report on Form 10-Q for the quarter http://www.streetinsider.com/Press+Releases/Celularity+Announces+Filing+of+Form+10-Q+Quarterly+Reports+for+the+First+Quarter+and+the+Second+Quarter+2025%2C+Confirmation+of+Nasdaq+Listing+Rule+5250%28c%29%281%29+Compliance/25288702.html Wed, 03 Sep 2025 08:00:00 -0400 CELU CELUW O.37572456 http://www.streetinsider.com/Globe+Newswire/Celularity+Announces+Filing+of+Form+10-Q+Quarterly+Reports+for+the+First+Quarter+and+the+Second+Quarter+2025%2C+Confirmation+of+Nasdaq+Listing+Rule+5250%28c%29%281%29+Compliance/25288702.html <ul><li style="text-align:left;">Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan.</li><li style="margin-bottom:8pt; text-align:left;">Company also announces notification by Nasdaq dated September 2, 2025, that it now complies with Nasdaq Listing Rule 5250(c)(1).</li></ul> <p>FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced the filing of its Quarterly Report on Form 10-Q for the quarter http://www.streetinsider.com/Globe+Newswire/Celularity+Announces+Filing+of+Form+10-Q+Quarterly+Reports+for+the+First+Quarter+and+the+Second+Quarter+2025%2C+Confirmation+of+Nasdaq+Listing+Rule+5250%28c%29%281%29+Compliance/25288702.html Wed, 03 Sep 2025 08:00:00 -0400 CELU CELUW O.37572456 http://www.streetinsider.com/Press+Releases/Celularity+Receives+Nasdaq+Notice+Regarding+Form+10-Q/25242069.html <p align="justify">FLORHAM PARK, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced that on August 21, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025. Based on this latest notice, the Company is not in compliance with Listing Rule 5250 (c)(1), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission.</p> http://www.streetinsider.com/Press+Releases/Celularity+Receives+Nasdaq+Notice+Regarding+Form+10-Q/25242069.html Fri, 22 Aug 2025 17:30:00 -0400 CELU CELUW O.37572456 http://www.streetinsider.com/Globe+Newswire/Celularity+Receives+Nasdaq+Notice+Regarding+Form+10-Q/25242069.html <p align="justify">FLORHAM PARK, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced that on August 21, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025. Based on this latest notice, the Company is not in compliance with Listing Rule 5250 (c)(1), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission.</p> http://www.streetinsider.com/Globe+Newswire/Celularity+Receives+Nasdaq+Notice+Regarding+Form+10-Q/25242069.html Fri, 22 Aug 2025 17:30:00 -0400 CELU CELUW O.37572456 http://www.streetinsider.com/Press+Releases/Celularity+Receives+Nasdaq+Notice+Regarding+Form+10-Q/25242069.html <p align="justify">FLORHAM PARK, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced that on August 21, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025. Based on this latest notice, the Company is not in compliance with Listing Rule 5250 (c)(1), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission.</p> http://www.streetinsider.com/Press+Releases/Celularity+Receives+Nasdaq+Notice+Regarding+Form+10-Q/25242069.html Fri, 22 Aug 2025 17:30:00 -0400 CELU CELUW O.37572456